Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients

British Journal of Cancer

Volumn 113, Issue 1, 2015, Pages 69-75

  Jennings, C J ^a   Murer, B ^b   O'Grady, A ^c   Hearn, L M ^a   Harvey, B J ^a   Kay, E W ^c   Thomas, W ^a,d  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b Dell'Angelo Hospital   (Italy)

^c BEAUMONT HOSPITAL   (Ireland)

^d PERDANA UNIVERSITY   (Malaysia)

Author keywords

cyclin dependent kinase inhibitor; Malignant pleural mesothelioma; p16 INK4A

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P16; CYCLIN DEPENDENT KINASE INHIBITOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DNA REPAIR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; TUMOR BIOPSY; VERY ELDERLY; MESOTHELIOMA; METABOLISM; PATHOLOGY; PLEURAL NEOPLASMS; TUMOR CELL LINE;

CELL LINE, TUMOR; COHORT STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 84934438631     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.187     Document Type: Article

References (35)

1. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85(3): 200-206.
2. Arima Y, Hayashi N, Hayashi H, Sasaki M, Kai K, Sugihara E, Abe E, Yoshida A, Mikami S, Nakamura S, Saya H (2012) Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer. Int J Cancer 130(11): 2568-2579.
3. Bahnassy AA, Zekri AR, Abou-Bakr AA, El-Deftar MM, El-Bastawisy A, Sakr MA, El-Sherif GM, Gaafar RM (2012) Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients. Exp Mol Pathol 93(1): 154-161.
4. Bianchi C, Bianchi T (2007) Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 45(3): 379-387.
5. Burke JR, Liban TJ, Restrepo T, Lee HW, Rubin SM (2014) Multiple mechanisms for E2F binding inhibition by phosphorylation of the retinoblastoma protein C-terminal domain. J Mol Biol 426(1): 245-255.
6. Cacciotti P, Strizzi L, Vianale G, Iaccheri L, Libener R, Porta C, Tognon M, Gaudino G, Mutti L (2002) The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am J Respir Cell Mol Biol 26(2): 189-193.
7. Dacic S, Kothmaier H, Land S, Shuai Y, Halbwedl I, Morbini P, Murer B, Comin C, Galateau-Salle F, Demirag F, Zeren H, Attanoos R, Gibbs A, Cagle P, Popper H (2008) Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch 453(6): 627-635.
8. Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J, Lee C, Yeoh C, Bains M, Rusch V (2007) Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2(10): 957-965.
9. Giglio S, Cirombella R, Amodeo R, Portaro L, Lavra L, Vecchione A (2013) MicroRNA miR-24 promotes cell proliferation by targeting the CDKs inhibitors p27Kip1 and p16INK4a. J Cell Physiol 228(10): 2015-2023.
10. Han S, Ahn SH, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY (2001) P16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy. Breast Cancer Res Treat 70(3): 205-212.
11. Harrington DP, Fleming TR (1982) A class of rank procedures for censored survival data. Biometrika 69: 553-566.
12. Ichimura T, Yamamura H, Sasamoto K, Tominaga Y, Taoka M, Kakiuchi K, Shinkawa T, Takahashi N, Shimada S, Isobe T (2005) 14-3-3 proteins modulate the expression of epithelial Na\+ channels by phosphorylationdependent interaction with Nedd4-2 ubiquitin ligase. J Biol Chem 280(13): 13187-13194.
13. Jennings CJ, O'Grady A, Cummins R, Murer B, Al-Alawi M, Madden SF, Mutti L, Harvey BJ, Thomas W, Kay EW (2012) Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma. J Thorac Oncol 7(1): 243-248.
14. Jennings CJ, Walsh PM, Deady S, Harvey BJ, Thomas W (2014) Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009. Cancer Epidemiol 38(1): 35-41.
15. Kanellou P, Zaravinos A, Zioga M, Stratigos A, Baritaki S, Soufla G, Zoras O, Spandidos DA (2008) Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis. Cancer Lett 264(1): 145-161.
16. Ke Y, Reddel RR, Gerwin BI, Reddel HK, Somers AN, McMenamin MG, LaVeck MA, Stahel RA, Lechner JF, Harris CC (1989) Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol 134(5): 979-991.
17. Kobayashi N, Toyooka S, Yanai H, Soh J, Fujimoto N, Yamamoto H, Ichihara S, Kimura K, Ichimura K, Sano Y, Kishimoto T, Date H (2008) Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer 62(1): 120-125.
18. Kudoh K, Ichikawa Y, Yoshida S, Hirai M, Kikuchi Y, Nagata I, Miwa M, Uchida K (2002) Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer. Int J Cancer 99(4): 579-582.
19. Le Stang N, Belot A, Gilg Soit Ilg A, Rolland P, Astoul P, Bara S, Brochard P, Danzon A, Delafosse P, Grosclaude P, Guizard AV, Imbernon E, Lapotre-Ledoux B, Ligier K, Molinie F, Pairon JC, Sauleau EA, Tretarre B, Velten M, Bossard N, Goldberg M, Launoy G, Galateau-Salle F (2010) Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005. Int J Cancer 126(1): 232-238.
20. Li J, Poi MJ, Tsai MD (2011) Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry 50(25): 5566-5582.
21. Li YL, Ye F, Hu Y, Lu WG, Xie X (2009) Identification of suitable reference genes for gene expression studies of human serous ovarian cancer by real-time polymerase chain reaction. Anal Biochem 394(1): 110-116.
22. Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, Illei PB, Hussain S, Krug L, Zakowski MF, Rusch V, Olshen AB, Ladanyi M (2006) Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66(6): 2970-2979.
23. Nilsson K, Landberg G (2006) Subcellular localization, modification and protein complex formation of the cdk-inhibitor p16 in Rb-functional and Rb-inactivated tumor cells. Int J Cancer 118(5): 1120-1125.
24. Nilsson K, Svensson S, Landberg G (2004) Retinoblastoma protein function and p16INK4a expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16INK4a expression and infiltrative behavior. Mod Pathol 17(12): 1464-1474.
25. Orengo AM, Spoletini L, Procopio A, Favoni RE, De Cupis A, Ardizzoni A, Castagneto B, Ribotta M, Betta PG, Ferrini S, Mutti L (1999) Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. Eur Respir J 13(3): 527-534.
26. Sanoff HK, Deal AM, Krishnamurthy J, Torrice C, Dillon P, Sorrentino J, Ibrahim JG, Jolly TA, Williams G, Carey LA, Drobish A, Gordon BB, Alston S, Hurria A, Kleinhans K, Rudolph KL, Sharpless NE, Muss HB (2014) Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst 106(4): dju057.
27. Sherr CJ (1996) Cancer cell cycles. Science 274(5293): 1672-1677.
28. Smythe WR, Kaiser LR, Hwang HC, Amin KM, Pilewski JM, Eck SJ, Wilson JM, Albelda SM (1994) Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 57(6): 1395-1401.
29. Spugnini EP, Campioni M, D'Avino A, Caruso G, Citro G, Baldi A (2007) Cell-cycle molecules in mesothelioma: an overview. J Exp Clin Cancer Res 26(4): 443-449.
30. Steele JP (2005) Prognostic factors for mesothelioma. Hematol Oncol Clin North Am 19(6): 1041-1052.
31. Sterman DH, Albelda SM (2005) Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 10(3): 266-283.
32. Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S, Yokoi K, Horio Y, Shimokata K, Sekido Y, Hida T (2006) Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci 97(5): 387-394.
33. Watkins JL, Lewandowski KT, Meek SE, Storz P, Toker A, Piwnica-Worms H (2008) Phosphorylation of the Par-1 polarity kinase by protein kinase D regulates 14-3-3 binding and membrane association. Proc Natl Acad Sci USA 105(47): 18378-18383.
34. Wong L, Zhou J, Anderson D, Kratzke RA (2002) Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 38(2): 131-136.
35. Xie QC, Hu YD, Wang LL, Chen ZT, Diao XW, Wang ZX, Guan HJ, Zhu B, Sun JG, Duan YZ, Chen FL, Nian WQ (2005) The co-transfection of p16(INK4a) and p14(ARF) genes into human lung cancer cell line A549 and the effects on cell growth and chemosensitivity. Colloids Surf B Biointerfaces 46(3): 188-196.